secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spyre Therapeutics, Inc. (SYRE)
CIK:        0001636282
Form:       8-K
Filed at:   2026-08-04T20:05:45+00:00
Accession:  0001636282-26-000098
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spyre reports Q2 net loss $36.2M; cash $1.15B; positive Phase 2 data for SPY001/SPY002 in UC
--------------------------------------------------------------------------------

- Net loss of $36.2M in Q2 2026 vs $36.7M in Q2 2025; R&D expenses rose to $65.5M from $40.1M.
- Cash, equivalents, and marketable securities of $1,145.3M as of June 30, 2026; raised $435.2M net in April 2026 public offering.
- SPY001 achieved 40% clinical remission and 51% endoscopic improvement; SPY002 achieved 33% and 42%, respectively, in Part A of SKYLINE UC trial.
- Enrollment completed for Phase 2 SKYWAY basket trial in RA, PsA, axSpA; RA data expected September 2026, PsA/axSpA data in Q4 2026.
- Recognized $40.0M gain on milestone from sale of priority review voucher related to legacy asset pegzilarginase.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636282/000163628226000098/0001636282-26-000098-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636282/000163628226000098/syre-20260804.htm
  HTML page:      https://secwatch.observer/filing/0001636282-26-000098

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer